Merck to Present Data on Mavenclad(R) and Rebif(R) in Relapsing Forms of Multiple Sclerosis at EAN
SergVladimirov 26 июн. | 10:45
DARMSTADT, Germany, June 14, 2018/PRNewswire/ -- Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of the European Academy of Neurology (EAN), taking place from June 16-19, in Lisbon, Portugal. Merck will present a total of 14 abstracts in the area of relapsing multiple sclerosis (RMS), including a post-hoc analysis of the Phase III CLARITY study, investigating whether the beneficial clinical and magnetic resonance imaging (MRI) effects of MAVENCLAD(R) are consistent in older (>50 years) and younger (less than or equal to50) adult patients with relapsing remitting MS (RRMS). Data presented at the congress will also provide further insights into the benefit-risk profile of MAVENCLAD(R) in patients with relapsing MS with high disease activity, using Multi-Criteria Decision Analysis, an EMA-recommended methodology used to indirectly compare the benefit-risk profile between treatments. A separate post hoc analysis of patients in the ONWARD study evaluates the efficacy of MAVENCLAD(R) as add-on to interferon beta-1a in patients with secondary progressive MS (SPMS) with relapses, compared to patients with RRMS from the same study.
Additionally, data presentations on Rebif(R) (interferon beta-1a) include analysis of MRI in MS (MAGNIMS) score[1] to predict long-term clinical disease activity (CDA)-free status and disability progression following treatment with Rebif(R).
In line with Merck's MS Inside Out campaign aiming to better understand patients with MS, results of the Merck-sponsored 'MS in the 21st Century International Unmet Needs Survey' show that MS patients have substantially different perceptions of the current unmet needs in MS compared to healthcare professionals (HCPs). Identification and understanding of these differences could lead to an improved dialogue between HCPs and patients, which is integral to finding appropriate individualised treatment approaches for each patient.
Attendees can learn more about Merck's programs, pipeline and activities in neurology and immunology by visiting the company`s medical booth A07
The following abstracts have been accepted for presentation at EAN Congress 2018:
https://www.prnewswire.com/news-releases/merck-to-present-data-on-mavenclad-and-rebif-in-relapsing-forms-of-multiple-sclerosis-at-ean-300666389.html
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About MAVENCLAD(R)
MAVENCLAD(R) (cladribine tablets) is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of multiple sclerosis (MS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD(R) for the treatment of relapsing forms of MS (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD(R) is now available in over 10 countries in Europe, plus Australia, Argentina and the United Arab Emirates. MAVENCLAD(R) is not yet approved for any use in the United States.
The clinical development program of MAVENCLAD(R) in MS comprises more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. These clinical trials include the Phase III CLARITY, CLARITY extension and ORACLE MS trials, the Phase II ONWARD trial and the PREMIERE Long-term Safety Registry.
EU Indication MAVENCLAD(R) (cladribine tablets) is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features.
Important EU Safety Information Contraindications: MAVENCLAD(R) is contraindicated in patients with hypersensitivity to the active substance, human immunodeficiency virus (HIV), active chronic infection (tuberculosis or hepatitis), active malignancy, moderate to severe renal impairment (creatinine clearance
Additionally, data presentations on Rebif(R) (interferon beta-1a) include analysis of MRI in MS (MAGNIMS) score[1] to predict long-term clinical disease activity (CDA)-free status and disability progression following treatment with Rebif(R).
In line with Merck's MS Inside Out campaign aiming to better understand patients with MS, results of the Merck-sponsored 'MS in the 21st Century International Unmet Needs Survey' show that MS patients have substantially different perceptions of the current unmet needs in MS compared to healthcare professionals (HCPs). Identification and understanding of these differences could lead to an improved dialogue between HCPs and patients, which is integral to finding appropriate individualised treatment approaches for each patient.
Attendees can learn more about Merck's programs, pipeline and activities in neurology and immunology by visiting the company`s medical booth A07
The following abstracts have been accepted for presentation at EAN Congress 2018:
https://www.prnewswire.com/news-releases/merck-to-present-data-on-mavenclad-and-rebif-in-relapsing-forms-of-multiple-sclerosis-at-ean-300666389.html
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About MAVENCLAD(R)
MAVENCLAD(R) (cladribine tablets) is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of multiple sclerosis (MS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD(R) for the treatment of relapsing forms of MS (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD(R) is now available in over 10 countries in Europe, plus Australia, Argentina and the United Arab Emirates. MAVENCLAD(R) is not yet approved for any use in the United States.
The clinical development program of MAVENCLAD(R) in MS comprises more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. These clinical trials include the Phase III CLARITY, CLARITY extension and ORACLE MS trials, the Phase II ONWARD trial and the PREMIERE Long-term Safety Registry.
EU Indication MAVENCLAD(R) (cladribine tablets) is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features.
Important EU Safety Information Contraindications: MAVENCLAD(R) is contraindicated in patients with hypersensitivity to the active substance, human immunodeficiency virus (HIV), active chronic infection (tuberculosis or hepatitis), active malignancy, moderate to severe renal impairment (creatinine clearance
